The analysis of <i>KRAS</i>, <i>NRAS</i> (codons 12, 13, 59, 61, 117, 146), and <i>BRAF</i> (codon 600) hotspot variants was performed in 161 CRC tumors from August 2018 to September 2021 and revealed three (1.8%) patients showing mutations in both <i>KRAS</i> and <i>BRAF</i> (V600E), including two cases with earlier CRC and one with metastatic disease. This evidence concerns the gene NRAS and metastatic neoplasm.